From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial

Last Updated: Monday, August 15, 2022

A prospective randomized, multicenter, phase 3 trial found that posttransplant cyclophosphamide (PT-Cy) combined with a short course of cyclosporine A found that PT-Cy after nonmyeloablative-matched allo-HSCT led to greater survival without severe GvHD.

Blood Advances
Advertisement
News & Literature Highlights
Advertisement
Advertisement